Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $7.9 million.

  • Amphastar Pharmaceuticals' Depreciation & Amortization (CF) fell 19.74% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year decrease of 20.51%. This contributed to the annual value of $28.2 million for FY2024, which is 9.76% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Depreciation & Amortization (CF) of $7.9 million as of Q3 2025, which was down 5.83% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $9.8 million in Q3 2024 and a low of $2.5 million during Q1 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $8.3 million in 2025 and averaged $7.8 million.
  • The largest annual percentage gain for Amphastar Pharmaceuticals' Depreciation & Amortization (CF) in the last 5 years was 215.90% (2024), contrasted with its biggest fall of 24.84% (2024).
  • Over the past 5 years, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $2.6 million in 2021, then soared by 32.28% to $3.4 million in 2022, then spiked by 180.86% to $9.7 million in 2023, then dropped by 24.84% to $7.3 million in 2024, then declined by 19.74% to $7.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $7.9 million in Q3 2025, compared to $8.3 million in Q2 2025 and $7.4 million in Q1 2025.